ATE400287T1 - Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit - Google Patents

Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit

Info

Publication number
ATE400287T1
ATE400287T1 AT02735312T AT02735312T ATE400287T1 AT E400287 T1 ATE400287 T1 AT E400287T1 AT 02735312 T AT02735312 T AT 02735312T AT 02735312 T AT02735312 T AT 02735312T AT E400287 T1 ATE400287 T1 AT E400287T1
Authority
AT
Austria
Prior art keywords
disease
treatment
neurodegenerative diseases
low dose
lhrh antagonists
Prior art date
Application number
AT02735312T
Other languages
German (de)
English (en)
Inventor
Juergen Engel
Rainer Voegeli
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Application granted granted Critical
Publication of ATE400287T1 publication Critical patent/ATE400287T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT02735312T 2001-04-30 2002-04-27 Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit ATE400287T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
ATE400287T1 true ATE400287T1 (de) 2008-07-15

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02735312T ATE400287T1 (de) 2001-04-30 2002-04-27 Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit

Country Status (27)

Country Link
US (1) US7288517B2 (enExample)
EP (1) EP1392348B1 (enExample)
JP (1) JP2004529207A (enExample)
KR (1) KR20040000446A (enExample)
CN (1) CN1317030C (enExample)
AT (1) ATE400287T1 (enExample)
AU (1) AU2002310788B2 (enExample)
BG (1) BG108339A (enExample)
BR (1) BR0209290A (enExample)
CA (1) CA2444876A1 (enExample)
CZ (1) CZ20033167A3 (enExample)
DE (1) DE60227507D1 (enExample)
DK (1) DK1392348T3 (enExample)
ES (1) ES2307760T3 (enExample)
HU (1) HUP0400067A2 (enExample)
IL (1) IL156777A0 (enExample)
MX (1) MXPA03008666A (enExample)
NO (1) NO20034322L (enExample)
NZ (1) NZ544417A (enExample)
PL (1) PL362319A1 (enExample)
PT (1) PT1392348E (enExample)
RU (1) RU2319501C2 (enExample)
SI (1) SI1392348T1 (enExample)
SK (1) SK14512003A3 (enExample)
UA (1) UA80679C2 (enExample)
WO (1) WO2002102401A1 (enExample)
ZA (1) ZA200305326B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
DK1300398T3 (da) 2000-07-05 2006-07-17 Astellas Pharma Inc Propan-1,3-dionderivat
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
JP4595938B2 (ja) 2004-06-04 2010-12-08 アステラス製薬株式会社 プロパン−１，３−ジオン誘導体又はその塩
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
ES2445791T3 (es) 2006-10-21 2014-03-05 Abbvie Deutschland Gmbh & Co Kg Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3
US20100204143A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
WO2009049742A2 (en) * 2007-09-11 2009-04-23 Mondobiotech Laboratories Ag Use of melanotrophin-potentiating factor as a therapeutic agent
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
CA2726247C (en) * 2008-05-29 2018-06-26 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
EP0901489A1 (en) * 1996-05-20 1999-03-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
NZ515460A (en) * 1999-05-14 2004-06-25 Neurocrine Biosciences Inc Imidazo- and pyrrolo[1,2-A]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
DE60022769T2 (de) * 1999-10-15 2006-07-06 Neurocrine Biosciences, Inc., San Diego Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen
AU2001248760A1 (en) 2000-04-13 2001-10-30 Takeda Chemical Industries Ltd. Preventives/remedies for alzheimer's disease
DK1300398T3 (da) 2000-07-05 2006-07-17 Astellas Pharma Inc Propan-1,3-dionderivat

Also Published As

Publication number Publication date
CA2444876A1 (en) 2002-12-27
US7288517B2 (en) 2007-10-30
PT1392348E (pt) 2008-09-09
PL362319A1 (en) 2004-10-18
KR20040000446A (ko) 2004-01-03
BG108339A (bg) 2004-11-30
HUP0400067A2 (hu) 2004-04-28
WO2002102401A1 (en) 2002-12-27
JP2004529207A (ja) 2004-09-24
UA80679C2 (en) 2007-10-25
ZA200305326B (en) 2003-07-30
ES2307760T3 (es) 2008-12-01
SI1392348T1 (sl) 2008-12-31
DE60227507D1 (de) 2008-08-21
NZ544417A (en) 2008-03-28
HK1072000A1 (en) 2005-08-12
EP1392348A1 (en) 2004-03-03
MXPA03008666A (es) 2004-10-15
US20020177556A1 (en) 2002-11-28
AU2002310788B2 (en) 2007-04-05
RU2319501C2 (ru) 2008-03-20
BR0209290A (pt) 2004-07-13
NO20034322D0 (no) 2003-09-26
CN1575185A (zh) 2005-02-02
EP1392348B1 (en) 2008-07-09
SK14512003A3 (sk) 2004-08-03
CN1317030C (zh) 2007-05-23
IL156777A0 (en) 2004-02-08
RU2003134949A (ru) 2005-02-10
NO20034322L (no) 2003-09-26
CZ20033167A3 (cs) 2004-08-18
DK1392348T3 (da) 2008-09-29

Similar Documents

Publication Publication Date Title
ATE400287T1 (de) Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
NO2016007I2 (no) Susoktokog
WO2002002518A3 (en) Compounds to treat alzheimer's disease
WO2002002520A8 (en) Compounds to treat alzheimer's disease
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
IS2613B (is) Útskipt díketópíperasín sem oxýtósínblokkar
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
DE60117541D1 (de) Candesartan zur Behandlung von Migräne
ATE298573T1 (de) Triazinonverbindungen zur behandlung von durch den befall mit parasitischen protozoen bedingten krankheiten
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen
EA200200987A1 (ru) Лечение заболеваний, связанных с серотонинергической системой
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
DE69634497D1 (de) Il-6 mutein
ATE480560T1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392348

Country of ref document: EP

REN Ceased due to non-payment of the annual fee